MeiraGTx Holdings PLC
MGTX7.430USD
+0.230+3.19%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
597.96MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über MeiraGTx Holdings PLC Unternehmen
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
MeiraGTx Holdings PLC Informationen
BörsenkürzelMGTX
Name des UnternehmensMeiraGTx Holdings PLC
IPO-datumJun 08, 2018
CEOForbes (Alexandria)
Anzahl der mitarbeiter381
WertpapierartOrdinary Share
GeschäftsjahresendeJun 08
Addresse655 Third Avenue
StadtNEW YORK
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl10017
Telefon16468607985
Websitehttps://meiragtx.com/
BörsenkürzelMGTX
IPO-datumJun 08, 2018
CEOForbes (Alexandria)
Führungskräfte von MeiraGTx Holdings PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
+174510.00%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
1.09M
+169762.00%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
682.92K
+59625.00%
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
168.34K
+31820.00%
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+75000.00%
Mr. Robert J. Wollin, J.D.
Mr. Robert J. Wollin, J.D.
General Counsel, Secretary
General Counsel, Secretary
52.08K
+25930.00%
Ms. Ellen Hukkelhoven, Ph.D.
Ms. Ellen Hukkelhoven, Ph.D.
Independent Director
Independent Director
--
--
Mr. Neil F. J. (Lord) Mendoza
Mr. Neil F. J. (Lord) Mendoza
Independent Director
Independent Director
--
--
Ms. Nicole Seligman
Ms. Nicole Seligman
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
+174510.00%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
1.09M
+169762.00%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
682.92K
+59625.00%
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
168.34K
+31820.00%
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+75000.00%
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Sanofi SA
15.15%
Perceptive Advisors LLC
12.77%
Johnson & Johnson Innovation-JJDC, Inc.
8.25%
Adage Capital Management, L.P.
5.20%
Prosight Capital
5.08%
Andere
53.54%
Aktionäre
Aktionäre
Anteil
Sanofi SA
15.15%
Perceptive Advisors LLC
12.77%
Johnson & Johnson Innovation-JJDC, Inc.
8.25%
Adage Capital Management, L.P.
5.20%
Prosight Capital
5.08%
Andere
53.54%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
26.91%
Corporation
16.02%
Private Equity
12.77%
Venture Capital
8.29%
Investment Advisor
7.72%
Individual Investor
4.74%
Investment Advisor/Hedge Fund
4.39%
Research Firm
2.26%
Pension Fund
0.09%
Andere
16.80%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
236
50.32M
62.51%
-4.52M
2025Q3
228
52.30M
65.02%
+2.51M
2025Q2
231
67.71M
84.26%
+4.10M
2025Q1
245
80.15M
99.86%
+3.86M
2024Q4
246
77.41M
99.87%
+22.10M
2024Q3
250
64.74M
84.14%
+9.72M
2024Q2
251
52.33M
80.03%
+4.22M
2024Q1
254
51.24M
78.85%
+2.58M
2023Q4
253
50.76M
80.27%
+3.66M
2023Q3
255
41.86M
71.40%
-5.70M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Sanofi SA
12.20M
15.15%
--
--
Sep 30, 2025
Perceptive Advisors LLC
10.28M
12.77%
-2.35M
-18.57%
Dec 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
6.64M
8.25%
--
--
Sep 30, 2025
Adage Capital Management, L.P.
4.18M
5.2%
-1.85M
-30.66%
Sep 30, 2025
Prosight Capital
4.09M
5.08%
-497.91K
-10.85%
Sep 30, 2025
Rubric Capital Management LP
3.73M
4.63%
--
--
Sep 30, 2025
683 Capital Management LLC
2.63M
3.26%
-65.00K
-2.42%
Sep 30, 2025
Millennium Management LLC
2.56M
3.18%
+1.78M
+226.16%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.39M
2.97%
-94.99K
-3.82%
Sep 30, 2025
J. Goldman & Co., L.P.
1.80M
2.24%
-243.64K
-11.92%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
Goldman Sachs Innovate Equity ETF
0.06%
Vanguard US Momentum Factor ETF
0.04%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
SPDR S&P International Small Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.07%
ProShares Ultra Nasdaq Biotechnology
Anteil0.07%
Invesco Nasdaq Biotechnology ETF
Anteil0.07%
Goldman Sachs Innovate Equity ETF
Anteil0.06%
Vanguard US Momentum Factor ETF
Anteil0.04%
iShares Biotechnology ETF
Anteil0.04%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.02%
iShares Russell 2000 Growth ETF
Anteil0.02%
SPDR S&P International Small Cap ETF
Anteil0.02%
iShares Russell 2000 Value ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
